Contineum Therapeutics, Inc. Class A (CTNM) AI Stock Analysis

• Market Cap: $473.22M
• Dividend Yield: N/A
• Average Volume (3M): 170.88K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.64
• Revenue Growth: N/A
• EPS Growth: -100.71%
• Country: US
• Employees: 41
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.49
• Shares Outstanding: 32,673,534
• 10 Day Avg. Volume: 105,448
• 30 Day Avg. Volume: 170,880
• PEG Ratio: 11.51
• Price to Book (P/B): 1.21
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -5.70
• Enterprise Value/Market Cap: 0.86
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -1.67K
• Enterprise Value/Ebitda: -6.42
• 1Y Price Target: $20.80
• Price Target Upside: 71.76% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): -2.2
• Revenue Forecast (FY): $2.83M

• Rating: 50 Neutral
• Price Target: $12.00 ▼(-0.91% Downside)
• Action: Reiterated Date: 03/06/26
• Date: Action: Reiterated 03/06/26

The score is held back primarily by weak financial performance (no recurring revenue, widening losses, and rising cash burn), partially offset by a stronger balance sheet and liquidity runway. Technical signals are mixed but not bearish, while valuation is difficult to anchor due to negative earnings and no dividend. Corporate updates support long-term execution potential but introduce dilution risk via the expanded ATM.

Positive Factors

Improved balance sheet and low leverage

A materially stronger equity base with very low debt provides durable financial flexibility to fund multi‑year clinical development and strategic options without reliance on high-cost borrowing. This reduces bankruptcy and liquidity risk, enabling sustained investment in pipeline execution over the medium term.

Large cash position and multi-year runway

A cash balance expected to fund operations into mid‑2029 materially lowers near‑term financing pressure, allowing management to advance Phase 2 programs and exploratory trials without immediate dependence on capital markets. That runway supports continuity of R&D and value‑creating milestones over several years.

Advancing clinical pipeline and strong partnerships

Progressing a randomized Phase 2 IPF study while leveraging external partnerships spreads development risk, brings validation from large pharma collaborators, and creates multiple commercialization paths. Structural benefits include de‑risked science, partner funding/support, and enhanced probability of future revenue streams.

Negative Factors

No recurring revenue and volatile revenue history

The absence of recurring revenue means the company remains dependent on successful clinical outcomes, milestone payments or capital raises to sustain operations. Revenue volatility limits predictability of cash inflows and increases the likelihood of future financing or partnership dependence to fund ongoing R&D.

Worsening cash burn and widening losses

Rapidly increasing operating outflows and deeper operating losses indicate the company is intensifying investment in trials without offsetting revenues. Persistently negative free cash flow erodes liquidity over time, raises financing frequency, and increases dilution risk if operating trends do not reverse through successful clinical progress.

Dilution risk from expanded ATM program

An enlarged at‑the‑market facility materially increases the company’s ability to raise equity opportunistically, which reduces immediate funding risk but raises long‑term shareholder dilution risk. Over multiple financing events this can dilute ownership and depress per‑share economics if revenue growth lags.

Contineum Therapeutics, Inc. Class A Business Overview & Revenue Model

Company Description

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

How the Company Makes Money

null

Contineum Therapeutics, Inc. Class A Financial Statement Overview

Summary

Financial profile is pressured by $0 revenue in 2024–2025, widening operating losses (EBIT -$68.1M in 2025), and worsening cash burn (operating cash flow -$55.3M in 2025). The key offset is a materially stronger balance sheet with higher equity ($261.0M) and modest debt ($8.3M), providing funding flexibility despite negative ROE.

Income Statement

Earnings quality and visibility are weak: revenue was $0 in 2024 and 2025 after a one-off $50.0M in 2023, and profitability swung from a $22.7M profit in 2023 to sizable losses in 2024 (-$42.3M) and 2025 (-$60.0M). Losses have also widened year over year (EBIT fell to -$68.1M in 2025 from -$50.9M in 2024), consistent with a biotech still in heavy investment mode. Strength: the 2023 result shows the model can produce meaningful profit when revenue is present, but the lack of recurring revenue and rising loss profile drives the low score.

Balance Sheet

Balance sheet strength improved materially: stockholders’ equity rose to $261.0M in 2025 from $198.1M in 2024, while total debt remains modest at $8.3M (low leverage, ~0.03 debt-to-equity). This provides financial flexibility to fund operations. Key weakness is ongoing value erosion from losses, reflected in negative return on equity (about -23% in 2025). Also notable: 2023 showed highly stressed capitalization (negative equity and very high effective leverage), highlighting historical volatility even though the more recent position is stronger.

Cash Flow

Cash burn is significant and worsening: operating cash flow was -$55.3M in 2025 versus -$32.8M in 2024, and free cash flow was similarly negative (-$55.5M in 2025). While 2023 generated positive operating cash flow ($19.3M) and free cash flow ($18.9M), the business reverted to heavy outflows thereafter. A relative positive is that cash flow tracks reported losses closely (free cash flow roughly in line with net income in 2024–2025), suggesting losses are not being masked by large non-cash distortions—however, the absolute burn level remains the dominant risk.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	50.00M	0.00	0.00
Gross Profit	-323.00K	-258.00K	50.00M	-329.00K	0.00
EBITDA	-68.06M	-42.00M	23.57M	-23.54M	-28.34M
Net Income	-59.98M	-42.26M	22.72M	-24.25M	-29.00M
Balance Sheet
Total Assets	276.64M	212.85M	130.39M	50.64M	70.52M
Cash, Cash Equivalents and Short-Term Investments	262.90M	204.76M	125.19M	47.24M	69.00M
Total Debt	8.25M	6.26M	193.19M	5.85M	4.91M
Total Liabilities	15.65M	14.78M	198.32M	11.37M	8.93M
Stockholders Equity	260.99M	198.07M	-67.94M	39.27M	61.59M
Cash Flow
Free Cash Flow	-55.54M	-33.36M	18.93M	-20.24M	-26.43M
Operating Cash Flow	-55.31M	-32.84M	19.35M	-20.12M	-26.27M
Investing Cash Flow	-3.71M	-69.74M	-65.57M	22.30M	-64.97M
Financing Cash Flow	112.69M	109.00M	56.18M	-1.24M	79.84M

Contineum Therapeutics, Inc. Class A Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 12.11
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTNM, the sentiment is Negative. The current price of 12.11 is below the 20-day moving average (MA) of 14.29, below the 50-day MA of 13.69, and above the 200-day MA of 10.22, indicating a neutral trend. The MACD of -0.44 indicates Positive momentum. The RSI at 37.04 is Neutral, neither overbought nor oversold. The STOCH value of 12.91 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CTNM.

Contineum Therapeutics, Inc. Class A Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CAPR	61 Neutral	$1.67B	-12.77	-0.14%	―	-52.08%	-69.35%
IMRX	56 Neutral	$324.56M	-5.17	-43.33%	―	―	9.32%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CTNM	50 Neutral	$473.22M	-5.28	-30.40%	―	―	-100.71%
DRTS	49 Neutral	$622.23M	-9.36	-57.29%	―	―	-22.82%
TVRD	46 Neutral	$33.02M	-16.53	-135.79%	―	-53.67%	86.75%
ENGN	46 Neutral	$482.99M	5.39	-5.15%	―	―	-52.86%

Contineum Therapeutics, Inc. Class A Corporate Events

Contineum Therapeutics Expands ATM Facility, Highlights Pipeline Progress

Contineum Therapeutics amended its existing at-the-market equity program with Leerink Partners on March 5, 2026, raising the total capacity for Class A common stock issuance to $100 million, excluding amounts already sold, while committing not to sell shares under the facility until after a lock-up expires on March 11, 2026. The same day, the company reported fourth-quarter 2025 results, highlighting a $262.9 million cash position expected to fund operations through mid-2029, initiation of patient dosing in its global Phase 2 PROPEL-IPF trial of PIPE-791 in idiopathic pulmonary fibrosis, progress in chronic pain and depression studies with partners including Johnson & Johnson, and a modest year-over-year increase in quarterly net loss to $15.2 million despite disciplined spending on its expanding clinical pipeline.

The company also outlined that PROPEL-IPF, a 26-week, randomized, double-blind, placebo-controlled Phase 2 trial, will evaluate the efficacy, safety and tolerability of once-daily oral PIPE-791 in about 324 patients with idiopathic pulmonary fibrosis. In parallel, Contineum is advancing an exploratory Phase 1b chronic pain trial of PIPE-791, with topline data expected in the second quarter of 2026, while Johnson & Johnson continues a Phase 2 Moonlight-1 study of PIPE-307 in major depressive disorder, underscoring Contineum’s strategy to prioritize its lead IPF program while leveraging partnerships to broaden its NI&I pipeline.

The most recent analyst rating on (CTNM) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Contineum Therapeutics, Inc. Class A stock, see the CTNM Stock Forecast page.

Contineum Therapeutics Adopts 2026 Employment Inducement Equity Plan

On January 23, 2026, Contineum Therapeutics, Inc.’s board approved a new 2026 Employment Inducement Equity Incentive Plan, modeled largely on its 2024 Equity Incentive Plan but limited to non-incentive stock options and awards granted only to individuals eligible under Nasdaq rules. Adopted without stockholder approval under Nasdaq Rule 5635(c)(4), the plan initially reserves 750,000 shares of Class A common stock and is designed to grant equity awards solely to new or returning employees as a material inducement to commence employment, underscoring the company’s use of stock-based incentives to attract and retain talent in a competitive market for specialized biopharmaceutical professionals.

The most recent analyst rating on (CTNM) stock is a Hold with a $11.50 price target. To see the full list of analyst forecasts on Contineum Therapeutics, Inc. Class A stock, see the CTNM Stock Forecast page.